PE20181364A1 - Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, metodos su elaboracion y metodos para su uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histaminico h4 (h4) - Google Patents
Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, metodos su elaboracion y metodos para su uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histaminico h4 (h4)Info
- Publication number
- PE20181364A1 PE20181364A1 PE2018000602A PE2018000602A PE20181364A1 PE 20181364 A1 PE20181364 A1 PE 20181364A1 PE 2018000602 A PE2018000602 A PE 2018000602A PE 2018000602 A PE2018000602 A PE 2018000602A PE 20181364 A1 PE20181364 A1 PE 20181364A1
- Authority
- PE
- Peru
- Prior art keywords
- compositions
- methods
- histamine
- receptor
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se refiere a composiciones que comprenden dihidrato de N4-(ciclopropilmetil)-6-[(3R)-3-(metilamino)pirrolidin-1-il]pirimidin-2,4-diamina tartrato, menos del 1% de 4-N-butil-6-[(3-(metilamino)pirrolidin-1-il]pirimidin-2,4-diamina y menos del 0,26% de impurezas. Dichas composiciones se emplean en el tratamiento de enfermedades inflamatorias mediadas por el receptor histaminico H4, como dermatitis atopica, asma, urticaria, nefropatia diabetica, entre otras.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562246482P | 2015-10-26 | 2015-10-26 | |
US201662329091P | 2016-04-28 | 2016-04-28 | |
US201662359066P | 2016-07-06 | 2016-07-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20181364A1 true PE20181364A1 (es) | 2018-08-27 |
Family
ID=57200025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2018000602A PE20181364A1 (es) | 2015-10-26 | 2016-10-25 | Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, metodos su elaboracion y metodos para su uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histaminico h4 (h4) |
Country Status (21)
Country | Link |
---|---|
US (2) | US20170158671A1 (es) |
EP (1) | EP3368528A1 (es) |
JP (1) | JP2018531288A (es) |
KR (1) | KR20180067683A (es) |
CN (1) | CN108602801A (es) |
AU (2) | AU2016344627B9 (es) |
BR (1) | BR112018007765A2 (es) |
CA (1) | CA3001636A1 (es) |
CL (1) | CL2018001092A1 (es) |
CO (1) | CO2018004323A2 (es) |
EC (1) | ECSP18038867A (es) |
HK (1) | HK1252050A1 (es) |
IL (1) | IL258813A (es) |
MX (1) | MX2018005140A (es) |
PE (1) | PE20181364A1 (es) |
PH (1) | PH12018500822A1 (es) |
RU (1) | RU2018119104A (es) |
SG (1) | SG11201802676QA (es) |
TW (1) | TW201729810A (es) |
WO (1) | WO2017072131A1 (es) |
ZA (1) | ZA201802183B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
WO2019073388A1 (en) * | 2017-10-09 | 2019-04-18 | Teva Pharmaceutical Industries Ltd. | NEW SALT AND FORMS IN THE STRONG STATE OF ESCITALOPRAM |
BR112020009889A2 (pt) | 2017-12-14 | 2020-11-03 | Flodesign Sonics, Inc. | acionador e controlador de transdutor acústico |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072548A2 (en) | 2001-03-09 | 2002-09-19 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic compounds and their use as histamine h4 ligands. |
DE60305052T2 (de) | 2002-09-06 | 2006-12-21 | Janssen Pharmaceutica N.V. | Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden |
KR101235116B1 (ko) * | 2005-10-17 | 2013-02-20 | 에스케이케미칼주식회사 | 광학활성 암로디핀 겐티세이트 염의 제조방법 |
NL2000323C2 (nl) * | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
JP2008127359A (ja) * | 2006-11-22 | 2008-06-05 | Kowa Co | アトピー性皮膚炎の予防及び/又は治療剤 |
US9688989B2 (en) * | 2012-06-08 | 2017-06-27 | Sensorion | H4 receptor inhibitors for treating tinnitus |
-
2016
- 2016-10-24 TW TW105134313A patent/TW201729810A/zh unknown
- 2016-10-25 US US15/333,713 patent/US20170158671A1/en not_active Abandoned
- 2016-10-25 US US15/770,825 patent/US20190135787A1/en not_active Abandoned
- 2016-10-25 KR KR1020187014495A patent/KR20180067683A/ko unknown
- 2016-10-25 RU RU2018119104A patent/RU2018119104A/ru not_active Application Discontinuation
- 2016-10-25 EP EP16785505.5A patent/EP3368528A1/en not_active Withdrawn
- 2016-10-25 AU AU2016344627A patent/AU2016344627B9/en not_active Ceased
- 2016-10-25 PE PE2018000602A patent/PE20181364A1/es unknown
- 2016-10-25 SG SG11201802676QA patent/SG11201802676QA/en unknown
- 2016-10-25 CA CA3001636A patent/CA3001636A1/en not_active Abandoned
- 2016-10-25 CN CN201680076200.2A patent/CN108602801A/zh active Pending
- 2016-10-25 JP JP2018540217A patent/JP2018531288A/ja active Pending
- 2016-10-25 MX MX2018005140A patent/MX2018005140A/es unknown
- 2016-10-25 WO PCT/EP2016/075708 patent/WO2017072131A1/en active Application Filing
- 2016-10-25 BR BR112018007765A patent/BR112018007765A2/pt not_active Application Discontinuation
-
2018
- 2018-04-04 ZA ZA2018/02183A patent/ZA201802183B/en unknown
- 2018-04-17 PH PH12018500822A patent/PH12018500822A1/en unknown
- 2018-04-18 IL IL258813A patent/IL258813A/en unknown
- 2018-04-24 CO CONC2018/0004323A patent/CO2018004323A2/es unknown
- 2018-04-25 CL CL2018001092A patent/CL2018001092A1/es unknown
- 2018-05-21 EC ECIEPI201838867A patent/ECSP18038867A/es unknown
- 2018-09-05 HK HK18111382.3A patent/HK1252050A1/zh unknown
-
2020
- 2020-02-06 AU AU2020200840A patent/AU2020200840A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CL2018001092A1 (es) | 2018-08-10 |
SG11201802676QA (en) | 2018-05-30 |
CA3001636A1 (en) | 2017-05-04 |
AU2016344627B2 (en) | 2019-11-07 |
EP3368528A1 (en) | 2018-09-05 |
RU2018119104A (ru) | 2019-11-28 |
BR112018007765A2 (pt) | 2018-10-23 |
AU2016344627A1 (en) | 2018-05-10 |
CN108602801A (zh) | 2018-09-28 |
IL258813A (en) | 2018-06-28 |
JP2018531288A (ja) | 2018-10-25 |
HK1252050A1 (zh) | 2019-05-10 |
RU2018119104A3 (es) | 2020-02-19 |
CO2018004323A2 (es) | 2018-07-19 |
KR20180067683A (ko) | 2018-06-20 |
US20170158671A1 (en) | 2017-06-08 |
PH12018500822A1 (en) | 2018-10-01 |
AU2020200840A1 (en) | 2020-02-27 |
TW201729810A (zh) | 2017-09-01 |
AU2016344627B9 (en) | 2019-11-28 |
MX2018005140A (es) | 2018-05-07 |
WO2017072131A1 (en) | 2017-05-04 |
US20190135787A1 (en) | 2019-05-09 |
ZA201802183B (en) | 2019-02-27 |
ECSP18038867A (es) | 2018-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20181364A1 (es) | Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, metodos su elaboracion y metodos para su uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histaminico h4 (h4) | |
CL2017003073A1 (es) | Inhibidores de tirosina-cinasas | |
CL2018001089A1 (es) | Sales de valbenazina y polimorfos de las mismas. | |
ECSP18001308A (es) | Derivados de oxopiridina sustituidos | |
NI200900159A (es) | Moduladores de 2-aminopirimidina del receptor de histamina h4. | |
BR112017015310A8 (pt) | uso de pgr4 como um agente anti-inflamatório | |
CR20150476A (es) | Oxopyridine derivados sustituidos y su uso en el tratamiento de trastornos cardiovasculares | |
PH12015501648B1 (en) | 2-aminopyrimidine derivatives for the treatment of viral infections | |
MX365294B (es) | Inhibidores de proteína cinasa dependiente de adn. | |
CL2016001055A1 (es) | Compuestos derivados de fenil-aminopirimidina, inhibidores de la tirosina quinasa de bruton (btk), composicion farmaceutica; combinacion farmaceutica; útiles en el tratamiento de enfermedades autoinmunes, inflamatorias, alergicas, de las vias aereas, entre otras. | |
CR20160501A (es) | Derivados de quinoxalina útiles como amortiguadores del receptor del factor de crecimiento de fibroblastos (fgfr) cinasa | |
UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
NI201000214A (es) | Moduladores de diamino-piridina, pirimidina, y piridazina del receptor de la histamina h4. | |
GT201500243A (es) | Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina | |
CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
CL2015003195A1 (es) | Derivados de purina como agonistas del receptor cb2. | |
CR20150653A (es) | Compuestos nuevos para el tratamiento del cáncer | |
CR20130094A (es) | Agonistas de adenosina a1 para el tratamiento del glaucoma y la hipertensión ocular | |
CR20150659A (es) | Derivados de prodroga de triazolpiridinas sustituidas | |
UY36732A (es) | Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet | |
PE20170313A1 (es) | Formulacion de ceritinib | |
NI201500172A (es) | Composiciones farmacéuticas | |
AR106577A1 (es) | Composiciones de pirimidina, composiciones ultrapuras y sus sales, sus métodos de preparación y sus métodos de uso para el tratamiento de enfermedades y condiciones mediadas por el receptor de histamina h4 (h4) | |
NI201500168A (es) | Benzoxazoles sustituidos | |
WO2015191635A3 (en) | Xanthine oxidase inhibitors and methods of use |